Sponsors have always been responsible for the trials they fund, even when a CRO performs most of the work. ICH E6(R3) makes that responsibility more explicit and more demanding. The updated guideline emphasizes quality by design, proportionate risk management, and meaningful oversight of every party involved in trial conduct. For executive leaders, this is so much more than a compliance footnote. It is a governance obligation.
Under E6(R3), sponsors are expected to understand the risks that are critical to participant safety and data reliability, and to direct oversight toward those risks. That requires leadership that can define what matters most for a given study and ensure the CRO relationship is structured to address it.
In practice, executive oversight starts before the contract is signed. Leaders should confirm that the scope of work, transfer of obligations, and quality agreements clearly describe who does what. Ambiguity at this stage becomes a finding at inspection.
Once the study is running, oversight must be active rather than passive. Reviewing monthly reports is not enough. Sponsors should have a documented oversight plan, defined key performance and quality indicators, and a governance structure that escalates issues quickly. Executive sponsors should attend governance meetings, challenge trends, and document decisions.
E6(R3) also highlights the use of technology and data systems. Leaders need confidence that the systems used by the CRO and other vendors are fit for purpose and that the sponsor can access the data it needs to oversee the trial. If the sponsor cannot see into its own study, oversight is weak by definition.
Smaller sponsors often feel this burden most. They may lack a dedicated quality function or a senior clinical operations leader with CRO management experience. This is where fractional executive leadership adds real value. An experienced leader can design a proportionate oversight model, set up governance, and coach the internal team to carry it forward.
The message of E6(R3) is simple: delegation does not remove accountability. ABRA Clinical Consulting helps sponsors build practical, risk-based CRO oversight frameworks that satisfy the guideline and support better trial outcomes.
